NCT06727331View on ClinicalTrials.gov

Study of Tirzepatide for Recovery and Alcohol Use Management

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

July 31, 2026

Conditions
Alcohol Use Disorder (AUD)
Interventions
DRUG

Tirzepatide

This intervention will consist of the FDA-approved dosing schedule. Participants will receive 2.5mg weekly injections for 4 weeks. IDS will extract tirzepatide and draw the doses into syringes.

OTHER

Saline Placebo

Placebo syringes of saline and matching volume will be produced by IDS.

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

02130

Brigham and Women's Faulkner Hospital, Jamaica Plain

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER